Annovis Bio Inc. - notizie pubblicate 172 - letture 3.536
ANNOVIS BIO INC.
Supplemental Prospectus - Form 424B5
Filed pursuant to rule 424(b)(5) registration no. 333-276814 prospectus supplement (to prospectus dated february 12, 2024) 316,455 shares of common stock we are offering 316,455 sh ...
ANNOVIS BIO INC.
Material Agreement - Form 8-K
Item 1.01 entry into a material definitive agreement. on march 21, 2024, annovis bio, inc. (the "company") entered into a securities purchase agreement (the "purchas ...
ANNOVIS BIO INC.
ANNOVIS BIO PROVIDES DATA ANNOUNCEMENT UPDATE FOR THE PHASE II/III STUDY OF BUNTANETAP IN ALZHEIMER’S DISEASE - Form 8-K
Annovis bio provides data announcement update for the phase ii/iii study of buntanetap in alzheimer's disease malvern, pa.-march 20, 2024 -- annovis bio, inc. (nyse: anvs), a clini ...
ANNOVIS BIO INC.
March 20, 2024Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Wed, 20 mar 2024 malvern, pa., march 20, 2024 (globe newswire) -- annovis bio, inc. (nyse: anvs), a clinical-stage drug platform company developing novel therapies for neurodegener ...
ANNOVIS BIO INC.
Material Event - Form 8-K
Item 8.01 other information. as disclosed on the form 8-k filed with the securities and exchange commission (the "commission") on march 15, 2024, annovis bio, inc. (the & ...
ANNOVIS BIO INC.
Supplemental Prospectus - Form 424B5
Tm248202-1_424b5 - none - 5.4843489s table of contents filed pursuant to rule 424(b)(5) registration no. 333-276814 prospectus supplement (to prospectus dated february 12, 2023) 11 ...
ANNOVIS BIO INC.
Supplemental Prospectus - Form 424B5
Tm248202-2_424b5 - none - 6.0468513s table of contents filed pursuant to rule 424(b)(5) registration no. 333-276814 prospectus supplement (to prospectus dated february 12, 2023) 11 ...
ANNOVIS BIO INC.
Material Agreement - Form 8-K
Item 1.01 entry into a material definitive agreement. on march 15, 2024, annovis bio, inc. (the "company") entered into a securities purchase agreement (the "purchas ...
ANNOVIS BIO INC.
Material Agreement - Form 8-K
Item 1.01 entry into a material definitive agreement. on march 15, 2024, annovis bio, inc. (the "company") entered into a securities purchase agreement (the "purchas ...
ANNOVIS BIO INC.
February 27, 2024Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
Tue, 27 feb 2024 malvern, pa., feb. 27, 2024 (globe newswire) -- annovis bio, inc. (nyse: anvs), a clinical-stage drug platform company developing novel therapies for neurodegenera ...
ANNOVIS BIO INC.
February 14, 2024Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Wed, 14 feb 2024 malvern, pa., feb. 14, 2024 (globe newswire) -- annovis bio, inc. (nyse: anvs), a clinical-stage drug platform company developing novel therapies for neurodegenera ...
ANNOVIS BIO INC.
Notice of Effectiveness - Form EFFECT
Notice of effectiveness united states securities and exchange commission washington, d.c. 20549 notice of effectiveness effectiveness date: february 12, 2024 4:15 p.m. form: s-3 ci ...
ANNOVIS BIO INC.
Registration Statement - Specified Transactions - Form S-3
Tm244399-1_s3 - none - 3.2187601s table of contents as filed with the securities and exchange commission on february 1, 2024 registration no. 333- united states securities and exch ...
ANNOVIS BIO INC.
January 30, 2024Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
Tue, 30 jan 2024 malvern, pa., jan. 30, 2024 (globe newswire) -- annovis bio, inc. (nyse: anvs), a clinical-stage drug platform company developing novel therapies for neurodegenera ...
ANNOVIS BIO INC.
January 24, 2024Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
Wed, 24 jan 2024 malvern, pa., jan. 24, 2024 (globe newswire) -- annovis bio, inc. (nyse: anvs), a clinical-stage drug platform company developing novel therapies for neurodegenera ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti